[Primary increase of fibrinolysis in a patient with metastatic carcinoma of the prostate (author's transl)].
D000347:Afibrinogenemia / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D000368:Aged; D000614:Aminocaproates / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001792:Blood Platelets; D001859:Bone Neoplasms; D002741:Chlorotrianisene / Q000627:therapeutic use; D003937:Diagnosis, Differential; D004211:Disseminated Intravascular Coagulation / Q000150:complications; D004997:Ethinyl Estradiol / Q000627:therapeutic use; D005340:Fibrinogen; D005342:Fibrinolysis; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D010756:Phosphoric Acids / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000150:complications*; D013267:Stilbenes / Q000627:therapeutic use
D000614:Aminocaproates; D000970:Antineoplastic Agents; D010756:Phosphoric Acids; D013267:Stilbenes; D004997:Ethinyl Estradiol; D002741:Chlorotrianisene; D005340:Fibrinogen; D006493:Heparin
Primäre Hyperfibrinolyse bei metastasierendem Prostatakarzinom